Conclusions
In conclusion, active surveillance testing for CRGNB may reduce its acquisition in clinical specimens in the ICU without additional costs. Individual hospitals should consider the cost-effectiveness of the intervention based on the baseline acquisition rate of CRGNB and the cost of intervention when they decide whether to adopt active surveillance testing.